603716.SH
塞力医疗
SSE · Healthcare · Medical - Diagnostics & Research · CN
CNY 15.07
−4.86%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 971.3M | 1.1B | 1.8B | 2.0B | 2.3B |
| Cost of Revenue | 753.1M | 836.6M | 1.5B | 1.6B | 1.9B |
| Gross Profit | 218.2M | 240.3M | 331.9M | 392.7M | 458.6M |
| Operating Expenses | |||||
| R&D Expense | 34.3M | 41.8M | 46.7M | 43.2M | 29.4M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 154.9M | 160.7M | 174.9M | 183.8M | 208.6M |
| Selling & Marketing Expense | 84.5M | 91.5M | 127.6M | 147.0M | 135.3M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 300.5M | 331.5M | 412.5M | 456.6M | 472.5M |
| Cost and Expenses | 1.1B | 1.2B | 1.9B | 2.1B | 2.3B |
| Operating Income (EBIT) | (155.6M) | (147.1M) | (141.8M) | (180.3M) | (148.5M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (160.7M) | (152.4M) | (148.3M) | (192.5M) | (191.7M) |
| Income Tax Expense | 46.2M | 49.1M | 45.1M | (35.7M) | (1.5M) |
| Bottom Line | |||||
| Net Income | (210.5M) | (207.3M) | (209.2M) | (158.6M) | (153.7M) |
| Earnings from Cont. Ops | (206.9M) | (201.4M) | (193.4M) | (156.8M) | (190.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (210.5M) | (207.3M) | (209.2M) | (158.6M) | (153.7M) |
| Per Share | |||||
| Basic EPS | (CN¥1.06) | (CN¥1.04) | (CN¥1.09) | (CN¥0.82) | (CN¥0.79) |
| Diluted EPS | (CN¥1.06) | (CN¥1.04) | (CN¥1.09) | (CN¥0.82) | (CN¥0.79) |
| Revenue Per Share | CN¥4.44 | CN¥5.40 | CN¥9.43 | CN¥10.37 | CN¥11.86 |
| Shares | |||||
| Basic Shares Outstanding | 219.0M | 199.3M | 192.0M | 193.4M | 194.6M |
| Diluted Shares Outstanding | 219.0M | 199.3M | 192.0M | 193.4M | 194.6M |
| Profitability Metrics | |||||
| EBITDA | — | (111.1M) | (95.8M) | (118.1M) | (64.6M) |
| D&A | — | 36.0M | 46.0M | 62.2M | 84.0M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026